PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
05-Dec-2020 Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020 Amgen
05-Dec-2020 Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia Sysmex Inostics GmbH
04-Dec-2020 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc.
04-Dec-2020 PhagoMed Selected as Leading Young European Biotech Company PhagoMed
04-Dec-2020 Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting Cellular Biomedicine Group
04-Dec-2020 Marizyme, Inc. Expands Executive Team, Board of Directors Marizyme, Inc.
04-Dec-2020 Pressure BioSciences Proposed Acquisition Partner Cannaworx, Inc. Announces December 2020 Launch Date for FDA Registered Immune Booster Pressure BioSciences, Inc.
04-Dec-2020 Contract Research Organizations (CROs) Market to Reach $64.4 Billion by 2027, Growing at a CAGR of 6.5% From 2020 With COVID-19 Impact- Meticulous Research® Analysis Meticulous Market Research Pvt. Ltd
04-Dec-2020 Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition Rigel Pharmaceuticals, Inc.
04-Dec-2020 Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab Alligator Bioscience
04-Dec-2020 Olympus Grows Respiratory Portfolio with Acquisition of Veran Medical Technologies, Inc. Olympus
04-Dec-2020 Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study Ascletis Pharma Inc.
04-Dec-2020 Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study Ascletis Pharma Inc.
03-Dec-2020 enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer enGene
03-Dec-2020 PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO(TM) (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels PANTHERx Rare Pharmacy
03-Dec-2020 TheraCell Announces Expanded License Agreement With Australian Biotechnologies TheraCell, Inc.
03-Dec-2020 Neuroglee Therapeutics to Attack Alzheimer's Disease Through Personalized AI-Powered Digital Therapeutics Neuroglee Therapeutics
03-Dec-2020 Neuroglee Therapeutics to Attack Alzheimer's Disease Through Personalized AI-Powered Digital Therapeutics Neuroglee Therapeutics
02-Dec-2020 Applied Cells Announces New MARS® Bar System Applied Cells Inc.
02-Dec-2020 UK biotech company ILC Therapeutics announces first international investment ILC Therapeutics